The Bay Area Tumor Institute NCI Community Oncology Research Program (BATI NCORP) is a consortium of three community and county hospitals and four private physician practices in Greater Oakland, California. It was founded in 1979 as a CGOP and converted to CCOP status in 1989. With a special emphasis on the recruitment of minority, low income, pediatric, non-English speaking, and female populations in two Bay Area counties, the BATI NCORP enables cancer patients and the general at risk population to participate in the clinical research of the National Cancer Trials Network (NCTN) such as The Alliance, SWOG, NSABP/RTOG (NRG), CTSU, COG, and SunCoast. The long term objectives and specific aims of the BATI NCORP include accrual to therapeutic, cancer control, prevention, screening, imaging, biospecimen and cancer care delivery research trials, and increased scientific interactions with the research bases. The BATI-NORCP will accrue 95% of all eligible pediatric oncology patients in the region and will excel in the recruitment of minority and female participants. The BATI Clinical Research Program offers a successful long-term track record, an organized and committed medical community, experienced physician investigators, institutional and financial support from the Bay Area Tumor Institute, and unusual access to African American, Hispanic, Asian, pediatric, underserved, and female populations.
This research seeks to improve public health by enabling physicians and cancer patients to participate in clinical trials research. The research outcomes are expected to lead to the identification and dissemination of improved methods to diagnose, treat and prevent cancer as well as seek methods and insights to improving cancer care delivery.
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95|
|Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95|
|Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69|
|Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31|
|Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9|